

REMARKS AND RESPONSE TO OFFICE ACTION

After entry of this paper, claims 56-69 are pending, all of which are new. The disclosure supports the amendments, which add no new matter. Support for the new claims is found throughout the disclosure with exemplary support as follows. Support for the new claims is at least at pages 38-58, and original claims 2-4.

35 U.S.C. § 112, first paragraph

The Office objected to the specification and rejected the claims as allegedly not enabled. As discussed below, Applicants respectfully request reconsideration of the rejection.

The amended claims have deleted reference to preventing cancer and the Office's objection on this basis should be moot.

The Office asserted that Applicants had provided insufficient data to support the claimed range of structures. The amended claims have a reduced range of structures, which addresses the Office's concerns. Also, the Office's attention is directed to Miyamoto, et al., *Proc. Natl. Acad. Sci. USA*, 100:4440-4444, 2003 (newly cited). This reference discloses activity for additional compounds, e.g., compounds 5, 16 and 17 at page 4441, which include structures within the scope of the claimed compounds.

In view of the foregoing, Applicants request reconsideration and withdrawal of the rejection.

35 U.S.C. § 112, second paragraph

The Office rejected claim 55 as allegedly being indefinite. Applicants traverse the rejection, but have not represented this claim with the new claims. The rejection should be moot. Applicants request withdrawal of the rejection.

OTHER MATTERS


Applicants request consideration of the references cited in the information disclosure statements that they submitted in August of 2002 and December of 2003. The Office does not appear to have considered those references.

5

Hollis-Eden Pharmaceuticals, Inc.,

10

Date: 9-3-04



Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
Phone: 858-320-2569
Fax: 858-558-6470

15